Healthcare Industry News: uterine fibroids
News Release - May 9, 2006
ETHICON, Inc. Completes Acquisition of Vascular Control Systems, Inc.
SOMERVILLE, N.J., May 9 (HSMN NewsFeed) -- ETHICON, Inc. today announced it has acquired Vascular Control Systems, Inc. (http://www.vascularcontrol.com), a privately held company focused on developing medical devices to treat fibroids and to control bleeding in obstetric and gynecologic applications. Terms of the transaction were not disclosed.uterine fibroids are a common women's health problem occurring in an estimated one-third of women over age 30. Fibroids, which are a leading indication for hysterectomy, can cause pelvic pain, heavy menstrual bleeding and infertility. The primary technology acquired by ETHICON is a uterine artery occlusion treatment that offers a minimally-invasive alternative to current therapies.
"This represents a strong, strategic fit with our gynecologic business," said Sheri S. McCoy, company group chairman for Johnson & Johnson with responsibility for the ETHICON franchise. "The technology and knowledge we'll gain will enable us to expand our ability to create new therapies for women."
ETHICON, a Johnson & Johnson company, is a global medical device company that develops and markets surgical products for use in general surgery, wound management, women's health and cardiovascular surgery. Headquartered in Somerville, New Jersey, ETHICON conducts business in 52 countries and employs approximately 9,000 employees in its various worldwide locations. For information about ETHICON and its products, visit http://www.ethicon.com.
Source: ETHICON
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
